Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Perspective Therapeutics Inc (CATX)

Perspective Therapeutics Inc (CATX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 344,185
  • Shares Outstanding, K 74,338
  • Annual Sales, $ 1,450 K
  • Annual Income, $ -79,280 K
  • EBIT $ -95 M
  • EBITDA $ -69 M
  • 60-Month Beta 1.75
  • Price/Sales 321.67
  • Price/Cash Flow N/A
  • Price/Book 1.56

Options Overview Details

View History
  • Implied Volatility 268.33% (+39.13%)
  • Historical Volatility 186.46%
  • IV Percentile 57%
  • IV Rank 21.80%
  • IV High 1,031.38% on 09/30/25
  • IV Low 55.61% on 04/17/25
  • Expected Move (DTE 13) 1.12 (23.82%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 308
  • Volume Avg (30-Day) 1,303
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 11,861
  • Open Int (30-Day) 6,639
  • Expected Range 3.59 to 5.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.36
  • Number of Estimates 7
  • High Estimate -0.29
  • Low Estimate -0.43
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.25 +109.33%
on 01/20/26
6.16 -23.54%
on 01/29/26
+1.90 (+67.62%)
since 01/06/26
3-Month
1.96 +140.92%
on 11/21/25
6.16 -23.54%
on 01/29/26
+2.48 (+111.21%)
since 11/06/25
52-Week
1.60 +194.38%
on 04/09/25
6.16 -23.54%
on 01/29/26
+1.30 (+38.12%)
since 02/06/25

Most Recent Stories

More News
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments...

CATX : 4.71 (+1.73%)
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The genomics in cancer care market is on a massive tear, projected to hit $69.16 billion by 2032 as doctors...

ONCY : 0.8859 (+5.89%)
BCT.TO : 5.70 (-0.52%)
ACRV : 1.6700 (+4.37%)
LLY : 1,058.18 (+3.66%)
BCTX : 4.18 (+0.24%)
GLSI : 29.00 (+15.13%)
CATX : 4.71 (+1.73%)
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference

Continued strong patient recruitment in neuroendocrine tumors for lead program VMT-α-NET sets the stage for submissions of robust clinical data package for presentation to more medical conferences in...

CATX : 4.71 (+1.73%)
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

Updated interim results with an additional ~13 weeks of follow-up since the prior update [ 212 Pb]VMT-α-NET continues to be well-tolerated Updated efficacy analysis suggests durable disease...

CATX : 4.71 (+1.73%)
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.  ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments...

CATX : 4.71 (+1.73%)
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

SEATTLE, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.  (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced...

CATX : 4.71 (+1.73%)
Perspective Therapeutics to Participate in Upcoming December Conferences

SEATTLE, Nov. 20, 2025 (GLOBE NEWSWIRE) -- November 20, 2025 – Perspective Therapeutics, Inc.  ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering...

CATX : 4.71 (+1.73%)
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Updated interim results from the Company’s [ 212 Pb]VMT-α-NET Phase 1/2a study supporting the therapy’s compelling overall clinical profile at the 5 mCi dose were presented at the ESMO Congress...

CATX : 4.71 (+1.73%)
Perspective Therapeutics to Participate in Upcoming November Conferences

SEATTLE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.  ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments...

CATX : 4.71 (+1.73%)
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

SEATTLE, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.  ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments...

CATX : 4.71 (+1.73%)

Business Summary

Perspective Therapeutics Inc. is a medical technology and radiopharmaceutical company which provide advanced treatment applications for cancers. The Company is the sole producer of Cesium-131 brachytherapy seeds. Perspective Therapeutics Inc., formerly known as Isoray Inc., is based in RICHLAND, Wash....

See More

Key Turning Points

3rd Resistance Point 5.17
2nd Resistance Point 4.98
1st Resistance Point 4.84
Last Price 4.71
1st Support Level 4.51
2nd Support Level 4.32
3rd Support Level 4.18

See More

52-Week High 6.16
Last Price 4.71
Fibonacci 61.8% 4.42
Fibonacci 50% 3.88
Fibonacci 38.2% 3.34
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar